SNY acquires KDS.AS for €5.45 cash—a 272% premium to Friday’s closing price: https://finance.yahoo.com/news/sanofi-offers-acquire-kiadis-308-060000220.html The $272% premium is one of the largest ever paid in a biotech buyout (see table in next post). The nominal deal value is ~$360M (€308M). SNY and KDS.AS inked a platform-licensing deal in Jul 2020 (#msg-156765531).